RE:RE:RE:RE:RE:RE:RE:RE:RE:Baxter Apparently Tigris is tracking Euphas 2 results
Euphas 1 was stopped early for ethical reasons, after only 64 patients with an ARR of > 20%
Tigris is Open Label .. so the Docs know the score or can easily figure it out.
Potential Ethical dilemma is correct.
Doing the math on potential lives saved on a potential eligible market of 140,000 patients annually with ESS, the mind boggles... even at 12 or 15 or 20% ARR
MM